---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-22-000068"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:14:19.729312+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q1 2022 revenue $164.9M, GAAP EPS -$0.26, adjusted EPS -$0.03; reiterates FY2022 guidance

## Summary
- Revenue $164.9M (+11% YoY ex-divested); GAAP EPS $(0.26) improved from $(0.52); adjusted EPS $(0.03) from $(0.06).
- Cash $339.2M, no debt; adjusted gross margin 71.1%, operating loss $2.8M improved from $3.3M.
- Segment: Hereditary cancer rev $70.9M (-7% YoY); Pharmacogenomics rev $29.3M (+66% YoY); Prenatal +35%.
- Reiterated FY2022 guidance: rev $670-700M; GAAP EPS $(0.90)-(0.70); adj EPS $0.00-$0.20.
- Launched Precise Tumor test, expanded MyRisk to 13 genes, partnered on liquid biopsy test.

## SEC filing metadata
- accession: 0000899923-22-000068
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992322000068/0000899923-22-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992322000068/mygn-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-22-000068
- JSON: https://secwatch.observer/filing/0000899923-22-000068.json
- Plain text: https://secwatch.observer/filing/0000899923-22-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.